The editorial’s central claim is provocative in its simplicity: for women’s cancers, the most powerful tool available to medicine may not be a new drug, a novel biomarker, or a next-generation sequencing platform, but the knowledge that already exists and has not been fully acted upon. Oncology, De Vivo observes, is drawn toward what is mysterious or technologically complex. Yet the four major women’s cancers repeatedly demonstrate that the limiting factor is rarely the science itself. More often, it is political will, health infrastructure, and the distribution of attention and resources that determine whether established interventions actually reach the women who need them.

Cervical cancer is presented as the clearest and most consequential example. Human papillomavirus vaccination combined with modern screening can render this cancer almost entirely preventable. Where these tools are implemented equitably, incidence and mortality plummet; where they are not, women—especially those who are poor, rural, or otherwise marginalized—continue to die of a disease for which effective prevention has existed for years. The editorial is blunt about what this means: the science is not the bottleneck. The failure is one of delivery, and it is measured in lives that could have been saved with vaccines and screening programs that already work.

Breast cancer tells a more complicated story, one of genuine progress shadowed by persistent gaps. Survival has improved substantially, and the understanding of tumor biology has become more nuanced, enabling increasingly targeted therapies. But the editorial highlights a set of unresolved problems that precision medicine has not solved: public confusion about screening remains widespread, investment in primary prevention is limited, and racial and socioeconomic disparities in stage at diagnosis and outcomes persist. De Vivo draws a pointed contrast—clinicians and researchers speak about precision treatment with ease, yet remain far less precise about prevention and about who actually has access to the best care. The implication is that the same rigor applied to molecular subtyping needs to be applied to the social and structural determinants that shape who is diagnosed late and who dies early.

Ovarian cancer represents a different kind of missed opportunity, one that occurs earlier in the disease pathway. Unlike cervical cancer, it lacks an effective population-level strategy for early detection, and primary prevention options beyond women with known high-risk mutations or surgical indications remain elusive. Symptoms are typically vague and easily dismissed, care is frequently delayed, and the epidemiological lens on modifiable risk factors is comparatively underused. The editorial suggests that this underuse is itself a choice—one that reflects where research funding and clinical attention have historically flowed rather than any inherent limit on what epidemiology can contribute. For a cancer so often detected at advanced stages, the potential value of better understanding modifiable risk is difficult to overstate.

Endometrial cancer, the most common gynecologic malignancy in many high-income countries, is the fourth pillar of the argument—and perhaps the most alarming. Its incidence is rising, particularly among younger and minoritized women, and the drivers are well characterized: obesity, metabolic health, hormonal exposures, and body weight across the life course all play central roles. In principle, this should make endometrial cancer a model disease for prevention, a cancer whose trajectory could be bent downward through interventions on known risk factors. Instead, the editorial notes, it remains under-recognized, and stark racial inequities in mortality reveal that access to care, clinician bias, and delayed diagnosis are literally life-and-death issues. A preventable cancer is becoming more common, and the burden is falling disproportionately on the women least equipped to bear it.

Across all four cancers, the editorial identifies a consistent set of themes. Risk factors are, to a meaningful degree, modifiable. Tools that demonstrably work are not equitably delivered. And women’s voices remain underrepresented when research priorities are set and health policy decisions are made. These are not independent problems; they reinforce one another. When the populations most affected by a disease have the least influence over how resources are allocated, the interventions that exist tend to be deployed where they are easiest to deliver rather than where they are most needed. The result is a persistent gap between what medicine knows and what patients experience.

The editorial also serves as a progress report on a concrete effort to change that dynamic. In 2025, Cancer Causes & Control launched a dedicated collection on women’s cancers, aiming to bring these issues into sharper focus. Now in its second year, the collection has drawn strong engagement from researchers, clinicians, and advocates—evidence, De Vivo writes, that there is both energy and appetite for this work. But she is careful to distinguish engagement from impact. The challenge ahead, as she frames it, is to convert that energy into action: to move from describing disparities to dismantling them, and from documenting risk factors to actually preventing disease. Description, in other words, is a necessary but insufficient stage; the standard the journal must now hold itself to is measurable change.

That framing carries implications well beyond a single journal or collection. For researchers, it suggests that studies quantifying yet another disparity or confirming yet another risk association should be designed with an explicit pathway toward intervention. For clinicians, it underscores that prevention counseling, equitable screening outreach, and attention to the social circumstances of patients are not peripheral to oncology but central to it. For policymakers, the message is starker still: the tools to prevent cervical cancer outright, to reduce breast cancer disparities, and to slow the rise of endometrial cancer already exist, and the cost of inaction is counted in preventable deaths. What remains is the harder work of building the infrastructure, funding the programs, and sustaining the political commitment to deliver them.

De Vivo closes with a standard that is both an aspiration and an accountability measure: women deserve nothing less than the full application of what is already known. The editorial does not call for a scientific breakthrough. It calls for something arguably more difficult—the alignment of existing knowledge, existing tools, and existing evidence with the populations that need them most. In an era when cancer research is often celebrated for its technological sophistication, the argument lands with unusual force. The power to prevent many women’s cancers is not waiting to be discovered. It is waiting to be used.

Subject of Research: Prevention and health equity in women's cancers, including cervical, breast, ovarian, and endometrial cancer

Article Title: Letter from the Editor-in-Chief: Women’s cancers and the power we are not yet using

Article References: De Vivo, I. (2026). Letter from the Editor-in-Chief: Women’s cancers and the power we are not yet using. Cancer Causes & Control, 37(9), Article 154. https://doi.org/10.1007/s10552-026-02233-1

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02233-1

Keywords: women's cancers, cervical cancer, breast cancer, ovarian cancer, endometrial cancer, HPV vaccination, cancer prevention, health disparities, cancer screening, health equity, obesity and cancer, Cancer Causes & Control

The emphasis of the research is on epigenetic aging, which pertains to the biological age of an individual as determined by changes in DNA methylation. DNA methylation is a chemical modification of DNA that plays a significant role in gene regulation and expression. As individuals age, the patterns of methylation change, which can reflect the overall health and aging process within the body. This study found that women with heightened biological age as indicated by their DNA methylation profiles had an increased likelihood of developing breast cancer, suggesting a direct connection between accelerated epigenetic aging and cancer risk.

The subject of this investigation specifically focuses on postmenopausal, non-Hispanic white women, a demographic known to face elevated breast cancer risks especially after menopause. The researchers conducted a detailed analysis of blood samples and discovered a stark correlation: women whose biological markers indicated they were aging more rapidly were statistically more likely to be diagnosed with breast cancer. Intriguingly, this risk was amplified in women who had undergone bilateral oophorectomy before natural menopause, an operation that results in a significant reduction of estrogen levels – a hormone integral to maintaining both breast health and overall physiological processes.

Understanding how estrogen plays a role in both aging and cancer susceptibility is critical. The study suggests that diminished lifetime estrogen exposure directly contributes to the acceleration of aging markers in women, thereby influencing their vulnerability to breast cancer. This finding is particularly relevant for health practitioners and researchers as it underlines the need for tailored approaches in assessing cancer risks in different populations of women, particularly those with varied reproductive histories.

Furthermore, the findings extend beyond biological demographics, as lifestyle factors significantly impact both epigenetic aging and breast cancer susceptibility. The research indicates that obesity is linked to accelerated biological aging, thereby further heightening the cancer risk in obese women. Conversely, the effects of hormone replacement therapy varied depending on the regimen’s type and duration, illustrating the complex relationship between hormonal interventions and cancer risk.

One of the key takeaways from this research is the potential for early detection, which remains a cornerstone of effective breast cancer treatment. The current framework for assessing breast cancer risk often includes conventional factors such as age, family history, and lifestyle habits; however, these determinants may not provide a comprehensive overview of an individual’s actual risk. By integrating a blood test that measures biological aging into the risk assessment protocol, clinicians may better identify high-risk individuals and develop personalized prevention strategies.

As the study points out, utilizing this blood test for routine health screenings for women could revolutionize how healthcare providers approach breast cancer detection. The practical implications are profound, providing women with actionable insights into their health that can empower them to take proactive steps in mitigating risk through healthy lifestyle changes. Enhancing awareness around epigenetic aging could lead to more effective health campaigns promoting balanced diets, regular physical activity, and medically supervised hormone therapies.

Although the findings present promising advancements in breast cancer risk assessment, the authors caution that additional studies are imperative. There remains a need for validation of these findings in broader and more diverse populations to establish the universal applicability of this blood test approach. However, this innovative research offers a non-invasive, cost-effective strategy to predict breast cancer risks, highlighting the intricate connections between genetic health, environmental influences, and disease susceptibility.

In summary, the study advances an intriguing narrative on the importance of biological aging in understanding breast cancer risk, particularly among older women. The exploration of DNA methylation and its implications for epigenetic aging provides new avenues for future research and potential applications in routine medical practice. There lies a collective responsibility among researchers, clinicians, and public health advocates to glean insights from these findings, aiming to enhance breast cancer prevention strategies that could ultimately save lives.

With the continued research into the applications of epigenetic markers in cancer risk evaluation, healthcare may witness a transformative approach to managing breast cancer, leading to safer, more informed health practices for women worldwide.

Subject of Research:
Article Title: DNA-methylation age and accelerated epigenetic aging in blood as a tumor marker for predicting breast cancer susceptibility
News Publication Date: January 21, 2025
Web References:
References:
Image Credits: © 2024 Jung et al.

Keywords: aging, DNA methylation-based marker of aging, pre-diagnostic DNA, breast cancer, tumorigenesis, postmenopausal women